In This Article:
In the last week, the United States market has been flat, yet it has shown a robust 21% increase over the past year, with earnings expected to grow by 14% annually in the coming years. In this context of overall market growth and stability, identifying high growth tech stocks involves looking for companies with strong innovation potential and solid financial health that can capitalize on these favorable conditions.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 29.07% | 27.57% | ★★★★★★ |
| Alkami Technology | 21.99% | 102.65% | ★★★★★★ |
| AVITA Medical | 27.78% | 55.33% | ★★★★★★ |
| TG Therapeutics | 29.48% | 45.20% | ★★★★★★ |
| Bitdeer Technologies Group | 51.86% | 122.49% | ★★★★★★ |
| Clene | 61.16% | 59.11% | ★★★★★★ |
| Alnylam Pharmaceuticals | 21.83% | 59.08% | ★★★★★★ |
| Blueprint Medicines | 22.38% | 55.79% | ★★★★★★ |
| Lumentum Holdings | 21.25% | 118.58% | ★★★★★★ |
| Travere Therapeutics | 30.33% | 61.73% | ★★★★★★ |
Click here to see the full list of 230 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Chimerix
Simply Wall St Growth Rating: ★★★★★☆
Overview: Chimerix, Inc. is a biopharmaceutical company focused on developing medicines aimed at improving and extending the lives of patients with life-threatening diseases, with a market capitalization of $456.88 million.
Operations: Chimerix generates revenue primarily from its pharmaceuticals segment, which reported $0.16 million. The company's focus is on developing treatments for life-threatening diseases.
Chimerix's recent FDA nod for accelerated review of dordaviprone, targeting rare H3 K27M-mutant diffuse glioma, underscores its strategic pivot towards specialized therapeutics—a niche but potentially lucrative segment. This development, coupled with a robust 54.1% projected annual revenue growth and an anticipated profit surge of 53.34%, positions the firm distinctively in the high-growth biotech arena. However, its current unprofitability and the highly volatile share price reflect inherent risks. The secured $30 million credit facility enhances financial flexibility but underscores reliance on external financing to fuel operations and R&D initiatives.
-
Dive into the specifics of Chimerix here with our thorough health report.
-
Assess Chimerix's past performance with our detailed historical performance reports.
MicroVision
Simply Wall St Growth Rating: ★★★★★☆
Overview: MicroVision, Inc. focuses on developing and selling lidar sensors and software for automotive safety and autonomous driving applications, with a market cap of $383.28 million.
Operations: The company generates revenue primarily from the sale and servicing of lidar hardware and software, totaling $8.15 million.